{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:45:44Z","timestamp":1787960744181,"version":"build-2784847793"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guangxi Science and Technology Base and Talent Project","award":["No.AD19245196"],"award-info":[{"award-number":["No.AD19245196"]}]},{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.82060430"],"award-info":[{"award-number":["No.82060430"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The National Natural Science Foundation of Guangxi","award":["No.2023GXNSFBA026164"],"award-info":[{"award-number":["No.2023GXNSFBA026164"]}]},{"name":"Guangxi Key Research and Development Project","award":["No.AB24010149"],"award-info":[{"award-number":["No.AB24010149"]}]},{"name":"Guangxi key Laboratory of Enhanced Recovery after Surgery for Gastrointestinal Cancer","award":["No.YYZS2020003"],"award-info":[{"award-number":["No.YYZS2020003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03978-y","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T10:51:03Z","timestamp":1763549463000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exploring ASPN as a pan-cancer biomarker with a focus on gastric cancer"],"prefix":"10.1007","volume":"16","author":[{"given":"Yue","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"issue":"3","key":"3978_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"3978_CR2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41571-021-00514-z","volume":"18","author":"I Soerjomataram","year":"2021","unstructured":"Soerjomataram I, Bray F. Planning for tomorrow: global cancer incidence and the role of prevention 2020\u20132070. Nat Rev Clin Oncol. 2021;18(10):663\u201372.","journal-title":"Nat Rev Clin Oncol"},{"issue":"37","key":"3978_CR3","doi-asserted-by":"publisher","first-page":"6165","DOI":"10.3748\/wjg.v19.i37.6165","volume":"19","author":"RA de Mello","year":"2013","unstructured":"de Mello RA, Marques AM, Ara\u00fajo A. HER2 therapies and gastric cancer: a step forward. World J Gastroenterol. 2013;19(37):6165\u20139.","journal-title":"World J Gastroenterol"},{"issue":"10229","key":"3978_CR4","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/S0140-6736(20)30164-1","volume":"395","author":"PL Bedard","year":"2020","unstructured":"Bedard PL, Hyman DM, Davids MS, Siu LL. Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet. 2020;395(10229):1078\u201388.","journal-title":"Lancet"},{"issue":"1","key":"3978_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155.","journal-title":"Mol Cancer"},{"issue":"12","key":"3978_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168085","volume":"11","author":"GD Cao","year":"2016","unstructured":"Cao GD, Xu XY, Zhang JW, Chen B, Xiong MM. Phosphorylated mammalian target of Rapamycin p-mTOR is a favorable prognostic factor than mTOR in gastric cancer. PLoS One. 2016;11(12):e0168085.","journal-title":"PLoS One"},{"issue":"8","key":"3978_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161219","volume":"11","author":"G-D Cao","year":"2016","unstructured":"Cao G-D, Chen K, Xiong M-M, Chen B. HER3, but not HER4, plays an essential role in the clinicopathology and prognosis of gastric cancer: a meta-analysis. PLoS ONE. 2016;11(8):e0161219.","journal-title":"PLoS ONE"},{"issue":"15","key":"3978_CR8","doi-asserted-by":"publisher","first-page":"12201","DOI":"10.1074\/jbc.M010932200","volume":"276","author":"P Lorenzo","year":"2001","unstructured":"Lorenzo P, Aspberg A, Onnerfjord P, Bayliss MT, Neame PJ, Heinegard D. Identification and characterization of asporin. A novel member of the leucine-rich repeat protein family closely related to decorin and biglycan. J Biol Chem. 2001;276(15):12201\u201311.","journal-title":"J Biol Chem"},{"issue":"15","key":"3978_CR9","doi-asserted-by":"publisher","first-page":"12212","DOI":"10.1074\/jbc.M011290200","volume":"276","author":"SP Henry","year":"2001","unstructured":"Henry SP, Takanosu M, Boyd TC, Mayne PM, Eberspaecher H, Zhou W, et al. Expression pattern and gene characterization of asporin. A newly discovered member of the leucine-rich repeat protein family. J Biol Chem. 2001;276(15):12212\u201321.","journal-title":"J Biol Chem"},{"issue":"2","key":"3978_CR10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/ng1496","volume":"37","author":"H Kizawa","year":"2005","unstructured":"Kizawa H, Kou I, Iida A, Sudo A, Miyamoto Y, Fukuda A, et al. An aspartic acid repeat polymorphism in Asporin inhibits chondrogenesis and increases susceptibility to osteoarthritis. Nat Genet. 2005;37(2):138\u201344.","journal-title":"Nat Genet"},{"issue":"3","key":"3978_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/bcr1732","volume":"9","author":"A Mackay","year":"2007","unstructured":"Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, Ashworth A, et al. Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res. 2007;9(3):R37.","journal-title":"Breast Cancer Res"},{"key":"3978_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.7150\/jca.4120","volume":"3","author":"B Castellana","year":"2012","unstructured":"Castellana B, Escuin D, Peir\u00f3 G, Garcia-Valdecasas B, V\u00e1zquez T, Pons C, et al. ASPN and GJB2 are implicated in the mechanisms of invasion of ductal breast carcinomas. J Cancer. 2012;3:175\u201383.","journal-title":"J Cancer"},{"issue":"3","key":"3978_CR13","first-page":"3191","volume":"17","author":"K Jiang","year":"2019","unstructured":"Jiang K, Liu H, Xie D, Xiao Q. Differentially expressed genes ASPN, COL1A1, FN1, VCAN and MUC5AC are potential prognostic biomarkers for gastric cancer. Oncol Lett. 2019;17(3):3191\u2013202.","journal-title":"Oncol Lett"},{"issue":"3","key":"3978_CR14","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1373\/clinchem.2011.171637","volume":"58","author":"EW Klee","year":"2012","unstructured":"Klee EW, Bondar OP, Goodmanson MK, Dyer RB, Erdogan S, Bergstralh EJ, et al. Candidate serum biomarkers for prostate adenocarcinoma identified by mRNA differences in prostate tissue and verified with protein measurements in tissue and blood. Clin Chem. 2012;58(3):599\u2013609.","journal-title":"Clin Chem"},{"issue":"6","key":"3978_CR15","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/bjc.2017.15","volume":"116","author":"A Rochette","year":"2017","unstructured":"Rochette A, Boufaied N, Scarlata E, Hamel L, Brimo F, Whitaker HC, et al. Asporin is a stromally expressed marker associated with prostate cancer progression. Br J Cancer. 2017;116(6):775\u201384.","journal-title":"Br J Cancer"},{"issue":"9","key":"3978_CR16","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.1021\/pr200527z","volume":"10","author":"A Turtoi","year":"2011","unstructured":"Turtoi A, Musmeci D, Wang Y, Dumont B, Somja J, Bevilacqua G, et al. Identification of novel accessible proteins bearing diagnostic and therapeutic potential in human pancreatic ductal adenocarcinoma. J Proteome Res. 2011;10(9):4302\u201313.","journal-title":"J Proteome Res"},{"issue":"1","key":"3978_CR17","first-page":"517","volume":"8","author":"J Wang","year":"2015","unstructured":"Wang J, Yu H, Ye L, Jin L, Yu M, Lv Y. Integrated regulatory mechanisms of miRNAs and targeted genes involved in colorectal cancer. Int J Clin Exp Pathol. 2015;8(1):517\u201329.","journal-title":"Int J Clin Exp Pathol"},{"key":"3978_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121827","volume":"290","author":"C-Z Huang","year":"2022","unstructured":"Huang C-Z, Zhou Y, Tong Q-S, Duan Q-J, Zhang Q, Du J-Z, et al. Precision medicine-guided co-delivery of ASPN siRNA and oxaliplatin by nanoparticles to overcome chemoresistance of colorectal cancer. Biomaterials. 2022;290:121827.","journal-title":"Biomaterials"},{"key":"3978_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108613","volume":"112","author":"T Sun","year":"2019","unstructured":"Sun T, Wu R, Ming L. The role of m6A RNA methylation in cancer. Biomed Pharmacother. 2019;112:108613.","journal-title":"Biomed Pharmacother"},{"issue":"6024","key":"3978_CR20","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1126\/science.1203543","volume":"331","author":"CL Chaffer","year":"2011","unstructured":"Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331(6024):1559\u201364.","journal-title":"Science"},{"issue":"8","key":"3978_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0255915","volume":"16","author":"D Basak","year":"2021","unstructured":"Basak D, Jamal Z, Ghosh A, Mondal PK, Dey Talukdar P, Ghosh S, et al. Reciprocal interplay between Asporin and decorin: implications in gastric cancer prognosis. PLoS ONE. 2021;16(8):e0255915.","journal-title":"PLoS ONE"},{"issue":"1","key":"3978_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1159\/000515458","volume":"62","author":"M Yashiro","year":"2021","unstructured":"Yashiro M, Hasegawa T, Yamamoto Y, Tsujio G, Nishimura S, Sera T, et al. Asporin expression on stromal cells and\/or cancer cells might be a useful prognostic marker in patients with diffuse-type gastric cancer. Eur Surg Res. 2021;62(1):53\u201360.","journal-title":"Eur Surg Res"},{"issue":"9","key":"3978_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001871","volume":"12","author":"P Maris","year":"2015","unstructured":"Maris P, Blomme A, Palacios AP, Costanza B, Bellahc\u00e8ne A, Bianchi E, et al. Asporin is a fibroblast-derived TGF-\u03b21 inhibitor and a tumor suppressor associated with good prognosis in breast cancer. PLoS Med. 2015;12(9):e1001871.","journal-title":"PLoS Med"},{"issue":"32","key":"3978_CR24","doi-asserted-by":"publisher","first-page":"52045","DOI":"10.18632\/oncotarget.10471","volume":"7","author":"D Simkova","year":"2016","unstructured":"Simkova D, Kharaishvili G, Korinkova G, Ozdian T, Such\u00e1nkov\u00e1-Kleplov\u00e1 T, Soukup T, et al. The dual role of Asporin in breast cancer progression. Oncotarget. 2016;7(32):52045\u201360.","journal-title":"Oncotarget"},{"issue":"7","key":"3978_CR25","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1158\/1541-7786.MCR-23-1069","volume":"22","author":"SD Muthukrishnan","year":"2024","unstructured":"Muthukrishnan SD, Qi H, Wang D, Elahi L, Pham A, Alvarado AG, et al. Low- and high-grade glioma-associated vascular cells differentially regulate tumor growth. Mol Cancer Res. 2024;22(7):656\u201367.","journal-title":"Mol Cancer Res"},{"issue":"16","key":"3978_CR26","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1161\/CIRCULATIONAHA.124.069864","volume":"150","author":"J Hong","year":"2024","unstructured":"Hong J, Medzikovic L, Sun W, Wong B, Ruffenach G, Rhodes CJ, et al. Integrative multiomics in the lung reveals a protective role of Asporin in pulmonary arterial hypertension. Circulation. 2024;150(16):1268\u201387.","journal-title":"Circulation"},{"issue":"2","key":"3978_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1376-9","volume":"10","author":"H Li","year":"2019","unstructured":"Li H, Zhang Z, Chen L, Sun X, Zhao Y, Guo Q, et al. Cytoplasmic asporin promotes cell migration by regulating TGF-\u03b2\/Smad2\/3 pathway and indicates a poor prognosis in colorectal cancer. Cell Death Dis. 2019;10(2):109.","journal-title":"Cell Death Dis"},{"issue":"45","key":"3978_CR28","doi-asserted-by":"publisher","first-page":"73402","DOI":"10.18632\/oncotarget.12336","volume":"7","author":"H Wu","year":"2016","unstructured":"Wu H, Jing X, Cheng X, He Y, Hu L, Wu H, et al. Asporin enhances colorectal cancer metastasis through activating the EGFR\/src\/cortactin signaling pathway. Oncotarget. 2016;7(45):73402\u201313.","journal-title":"Oncotarget"},{"issue":"6","key":"3978_CR29","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.2741\/4774","volume":"24","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Li H, Zhao Y, Guo Q, Yu Y, Zhu S, et al. Asporin promotes cell proliferation via interacting with PSMD2 in gastric cancer. Front Biosci (Landmark Ed). 2019;24(6):1178\u201389.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"3978_CR30","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.canlet.2017.04.001","volume":"398","author":"L Wang","year":"2017","unstructured":"Wang L, Wu H, Wang L, Zhang H, Lu J, Liang Z, et al. Asporin promotes pancreatic cancer cell invasion and migration by regulating the epithelial-to-mesenchymal transition (EMT) through both autocrine and paracrine mechanisms. Cancer Lett. 2017;398:24\u201336.","journal-title":"Cancer Lett"},{"key":"3978_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.762180","volume":"12","author":"S Zhan","year":"2022","unstructured":"Zhan S, Wang T, Li J, Zhu H, Ge W, Li J. Asporin interacts with HER2 to promote thyroid cancer metastasis via the MAPK\/EMT signaling pathway. Front Oncol. 2022;12:762180.","journal-title":"Front Oncol"},{"issue":"7467","key":"3978_CR32","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature12626","volume":"501","author":"MR Junttila","year":"2013","unstructured":"Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501(7467):346\u201354.","journal-title":"Nature"},{"issue":"6230","key":"3978_CR33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348(6230):74\u201380.","journal-title":"Science"},{"key":"3978_CR34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.semcancer.2013.12.009","volume":"25","author":"O De Wever","year":"2014","unstructured":"De Wever O, Van Bockstal M, Mareel M, Hendrix A, Bracke M. Carcinoma-associated fibroblasts provide operational flexibility in metastasis. Semin Cancer Biol. 2014;25:33\u201346.","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"3978_CR35","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1158\/1078-0432.CCR-15-0256","volume":"22","author":"PJ Hurley","year":"2016","unstructured":"Hurley PJ, Sundi D, Shinder B, Simons BW, Hughes RM, Miller RM, et al. Germline variants in Asporin vary by race, modulate the tumor microenvironment, and are differentially associated with metastatic prostate cancer. Clin Cancer Res. 2016;22(2):448\u201358.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3978_CR36","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.pan.2020.01.003","volume":"20","author":"SP Pothula","year":"2020","unstructured":"Pothula SP, Pirola RC, Wilson JS, Apte MV. Pancreatic stellate cells: aiding and abetting pancreatic cancer progression. Pancreatology. 2020;20(3):409\u201318.","journal-title":"Pancreatology"},{"issue":"14","key":"3978_CR37","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1158\/0008-5472.CAN-18-2931","volume":"79","author":"RM Hughes","year":"2019","unstructured":"Hughes RM, Simons BW, Khan H, Miller R, Kugler V, Torquato S, et al. Asporin restricts mesenchymal stromal cell differentiation, alters the tumor microenvironment, and drives metastatic progression. Cancer Res. 2019;79(14):3636\u201350.","journal-title":"Cancer Res"},{"issue":"1","key":"3978_CR38","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/1878-0261.13077","volume":"16","author":"G Itoh","year":"2022","unstructured":"Itoh G, Takagane K, Fukushi Y, Kuriyama S, Umakoshi M, Goto A, et al. Cancer-associated fibroblasts educate normal fibroblasts to facilitate cancer cell spreading and T-cell suppression. Mol Oncol. 2022;16(1):166\u201387.","journal-title":"Mol Oncol"},{"key":"3978_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154462","volume":"245","author":"K Zhang","year":"2023","unstructured":"Zhang K, Yue B, Duan X, Chen W, Dai X, Chen Y, et al. Joint analysis identified FAP as a prognostic and diagnostic biomarker correlated immune infiltration in gastric cancer. Pathol Res Pract. 2023;245:154462.","journal-title":"Pathol Res Pract"},{"issue":"16","key":"3978_CR40","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-22-0121","volume":"28","author":"K-W Lee","year":"2022","unstructured":"Lee K-W, Van Cutsem E, Bang Y-J, Fuchs CS, Kudaba I, Garrido M, et al. Association of tumor mutational burden with efficacy of Pembrolizumab\u2009\u00b1\u2009chemotherapy as first-line therapy for gastric cancer in the phase III KEYNOTE-062 study. Clin Cancer Res. 2022;28(16):3489\u201398.","journal-title":"Clin Cancer Res"},{"key":"3978_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3593","author":"R Cristescu","year":"2018","unstructured":"Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018. https:\/\/doi.org\/10.1126\/science.aar3593.","journal-title":"Science"},{"issue":"8","key":"3978_CR42","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/annonc\/mdz116","volume":"30","author":"C Luchini","year":"2019","unstructured":"Luchini C, Bibeau F, Ligtenberg MJL, Singh N, Nottegar A, Bosse T, et al. Esmo recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1\/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019;30(8):1232\u201343.","journal-title":"Ann Oncol"},{"issue":"6","key":"3978_CR43","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","volume":"7","author":"J Chao","year":"2021","unstructured":"Chao J, Fuchs CS, Shitara K, Tabernero J, Muro K, Van Cutsem E, et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol. 2021;7(6):895\u2013902.","journal-title":"JAMA Oncol"},{"issue":"21","key":"3978_CR44","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1056\/NEJMra023075","volume":"349","author":"JG Herman","year":"2003","unstructured":"Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349(21):2042\u201354.","journal-title":"N Engl J Med"},{"issue":"9","key":"3978_CR45","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.7150\/thno.54967","volume":"11","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Chen Y, Jin M, Wang J. The crosstalk between m(6)A RNA methylation and other epigenetic regulators: a novel perspective in epigenetic remodeling. Theranostics. 2021;11(9):4549\u201366.","journal-title":"Theranostics"},{"issue":"2","key":"3978_CR46","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nbt.3391","volume":"34","author":"MT Chang","year":"2016","unstructured":"Chang MT, Asthana S, Gao SP, Lee BH, Chapman JS, Kandoth C, et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol. 2016;34(2):155\u201363.","journal-title":"Nat Biotechnol"},{"issue":"11","key":"3978_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.153154","volume":"216","author":"HJ Son","year":"2020","unstructured":"Son HJ, Choi EJ, Yoo NJ, Lee SH. Cancer-related gene mutations of ASPN in colon cancers. Pathol Res Pract. 2020;216(11):153154.","journal-title":"Pathol Res Pract"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03978-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03978-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03978-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T12:04:20Z","timestamp":1763553860000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03978-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3978"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03978-y","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2134"}}